Incannex Completes Dosing Patients in Phase 2 Proof-of-Concept Trial of IHL-42X for the Treatment of Obstructive Sleep Apnoea

Incannex Healthcare Limited (ASX:IHL), (‘Incannex” or the ‘Company’) a clinical stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that it has completed dosing of participants in the phase 2, proof-of-concept clinical trial investigating novel cannabinoid combination product, IHL-42X, for the treatment of obstructive sleep apnoea (“OSA”). The Company also announced that it has commenced preparation of a pre-Investigational New Drug (IND) meeting package and is targeting a pre-IND meeting with the U.S. Food and Drug Administration (FDA) in Q1 2022.